Aspen Neuroscience Prices IPO at Low End of Expectations
The clinical-stage biotech priced nearly 9.4 million shares at $15, raising about $140.6 million. Trading is slated to begin Friday.
Related stories
AIG to Buy Everest Group's Chile Insurance Operations
M impact | MNA | Oct 30, 2026, 02:30 PM UTC
How I’m Trading Musk’s Potential $3.5 Billion Merger
What if you’re right about Elon Musk’s next big move — but holding the wrong stock?
H impact | MNA | Oct 30, 2026, 01:45 PM UTC
UniCredit Seeks to Reassure German Businesses Over Commerzbank Takeover
CEO Andrea Orcel said UniCredit intends to build on both banks’ existing networks and customer relationships rather than reduce services. The German government, which holds a stake
M impact | MNA | Oct 30, 2026, 01:03 PM UTC
BASF Says Evonik Rebuffed $12.5 Billion Takeover Bid
BASF said Evonik Industries refused to enter talks over its $12.5 billion takeover bid. Evonik said it received an approach from BASF last week.
H impact | MNA | Oct 30, 2026, 12:10 PM UTC
Simon Property to Buy Seattle’s University Village Retail Center
M impact | MNA | Oct 30, 2026, 12:01 PM UTC
Autobuses de Leon Offers to Buy Mobico for About £308 Million
A report says Spanish transport company Autobuses de Leon made an offer to buy Mobico Group, valuing the British transport company at about £308 million ($412 million).
H impact | MNA | Oct 30, 2026, 09:44 AM UTC